Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $481.93, for a total transaction of $1,927,720.00. Following the transaction, the chief executive officer directly owned 130 shares in the company, valued at $62,650.90. The trade was a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

United Therapeutics Stock Down 1.2%

UTHR stock traded down $5.81 during trading on Tuesday, reaching $474.14. The stock had a trading volume of 308,992 shares, compared to its average volume of 584,417. The company has a market capitalization of $20.42 billion, a price-to-earnings ratio of 17.97, a P/E/G ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $492.62. The company’s 50 day moving average is $448.96 and its two-hundred day moving average is $363.80.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company’s revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.39 EPS. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB lifted its stake in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Chung Wu Investment Group LLC bought a new stake in United Therapeutics during the 2nd quarter valued at $29,000. Abich Financial Wealth Management LLC bought a new stake in United Therapeutics during the 3rd quarter valued at $44,000. SVB Wealth LLC purchased a new stake in shares of United Therapeutics during the first quarter worth $32,000. Finally, WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of a number of recent analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a report on Monday. Oppenheimer boosted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Finally, Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.